Citation: Hr. Peng et al., Cdc25A Protein phosphatase inhibitors from anomalous ozonolysis of 5,6-seco-5-oxo-3-cholesten-6-oic acid, TETRAHEDRON, 57(10), 2001, pp. 1891-1896
Authors:
Peng, HR
Xie, WG
Otterness, DM
Cogswell, JP
McConnell, RT
Carter, HL
Powis, G
Abraham, RT
Zalkow, LH
Citation: Hr. Peng et al., Syntheses and biological activities of a novel group of steroidal derived inhibitors for human CDC25A protein phosphatase, J MED CHEM, 44(5), 2001, pp. 834-848
Authors:
Lewis, LD
Benin, A
Szumlanski, CL
Otterness, DM
Lennard, L
Weinshilboum, RM
Nierenberg, DW
Citation: Ld. Lewis et al., Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction (vol 62, pg 464, 1997), CLIN PHARM, 67(4), 2000, pp. 431-431
Authors:
Sekulic, A
Hudson, CC
Homme, JL
Yin, P
Otterness, DM
Karnitz, LM
Abraham, RT
Citation: A. Sekulic et al., A direct linkage between the phosphoinositide 3-Kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells, CANCER RES, 60(13), 2000, pp. 3504-3513
Citation: L. Yan et al., Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization, PHARMACOGEN, 9(3), 1999, pp. 307-316
Citation: Rm. Weinshilboum et al., Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase, ANN R PHARM, 39, 1999, pp. 19-52